T-cell non-Hodgkin's lymphomas develop following transformation of tissue resident T-cells.
We performed a meta-analysis of whole exome sequencing data from 403 patients with …

T cell lymphomas (TCL) comprise a heterogeneous group of non-Hodgkin lymphomas
(NHL) that often present at an advanced stage at the time of diagnosis and that most …

Simple Summary Anaplastic large cell lymphoma is a rare type of disease that occurs
throughout the world and has four subtypes. A summary and comparison of these subtypes …

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included
provisional entity in the 2016 revision of the World Health Organization classification, is a …

Simple Summary ALK-anaplastic large cell lymphoma (ALK-ALCL) is a rare subtype of
CD30+ large T-cell lymphoma that typically affects older adults and has a poor prognosis …

Treatment of high-risk neuroblastoma typically incorporates multiagent chemotherapy,
surgery, radiation therapy, autologous stem cell transplantation, immunotherapy, and …

Objectives This review describes our approach to the diagnosis of all 4 anaplastic large cell
lymphoma (ALCL) entities. Methods ALCLs are a group of CD30-positive mature T-cell …

In 2004, a chemical inhibitor of the kinase activity of EGFR was reported to be effective in a
subset of lung cancer patients with activating somatic mutations of EGFR. It remained …

Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) account for~ 10% and
2%–3% of all cases of lymphoid neoplasms, respectively. Up to 30% of patients with HL are …

Abstract Purpose of Review The recent development of brentuximab vedotin (BV), an
antibody-drug conjugate targeting CD30-positive cells, has led to therapeutic advances in …